Screener / SEC EDGAR /CIK 0001104506 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

INSMED Inc INSM

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of INSM's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Dec 21, 2020
Questions asked 3 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 3 numbered comments
  3. 3. Company replies 3 CORRESP
  4. 4. Reviews closed 2 of 2 closing letter

Half the closed reviews took 49 days or less from the first letter to the closing letter.

Form 10-K

2020-12-21 to 2021-01-05 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2021-01-05
Revenue
Financial Statements · Consolidated Statements of Comprehensive Loss, page 77
SEC asked
Please note that since you report amortization of intangible assets outside of cost of product revenue, it is not appropriate to present a separate caption for gross margin. Refer to SAB Topic 11:B and revise your presentation to either reclassify the applicable amortization to cost of product revenues or remove the caption gross margin.
INSM answered
The Company respectfully acknowledges the

Staff’s comment. In response to the Staff’s comment, in future filings, the Company will no longer present a gross margin caption in its consolidated statements of comprehensive loss.

We acknowledge that we are responsible for the adequacy and accuracy of the Company’s disclosures, notwithstanding any review, comments, action or absence of action by the Staff.

700

US Highway 202/206 | Bridgewater, NJ 08807 | Phone: 908-977-9900 | Fax: 908-526-4026 www.insmed.com

Correspondence regarding this letter may be directed to the attention of the
Rest of the answer

undersigned at [email protected]. In addition, you may contact me at (732) 487-7513 or Christine Pellizzari at (732) 487-7366.

Read in the reply
In its next report

First report after the company's reply of Dec 30, 2020: 10-K filed Feb 25, 2021 ↗, against the 10-K filed Feb 25, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2021-01-05

Form 10-K

2019-12-04 to 2020-01-22 · 2 questions · 2 letters from the SEC, 2 from the company
Review closed 2020-01-22
RevenueNon-GAAP measures
After reviewing your response to these comments, we may have additional comments. Exhibit 99.1 · Non-GAAP Financial Measures, page 3
SEC asked
We note you exclude costs of product revenues (excluding amortization) and milestone payments related to ARIKAYCE to arrive at your non-GAAP measure, Cash-Based Operating Expenses. Please tell us how you considered the guidance in Question 100.01 of the Non-GAAP Compliance and Disclosure Interpretations, as these costs appear to be normal, recurring cash operating expenses.
Rest of the question

We also note that the title "Cash-Based Operating Expenses" may imply that these expenses have been accounted for on a cash basis of accounting rather than on an accrual basis. Please revise the title or explain why you believe it is appropriate.

INSM answered
The Company acknowledges the Staff’s comment and intends to expand its future disclosure to highlight the nature of its research funding arrangement with Cystic Fibrosis Foundation Therapeutics, Inc. and how it differs from the Company’s license agreements.

* * * * *

Correspondence regarding this letter may be directed to the attention of the undersigned at [email protected]. In addition, you may contact me at (732) 487-7395 or Christine Pellizzari at (732) 487-7366.
Read in the reply
In its next report

First report after the company's reply of Jan 21, 2020: 10-K filed Feb 25, 2020 ↗, against the 10-K filed Feb 22, 2019 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

SEC letter of Jan 14, 2020 ↗ no reply letter on EDGAR
After reviewing your response to these comments, we may have additional comments. Exhibit 99.1, page 3
SEC asked
We note your response to our comment from our letter dated December 4, 2019. In order to distinguish your Arikayce milestone payments from your other more typical milestone payments, please expand your disclosures to highlight the nature of your research funding arrangement with the Cystic Fibrosis Foundation and how the arrangement differs from your other license agreements.
INSM answered

No reply letter found.

In its next report

First report after the SEC's letter of Jan 14, 2020: 10-K filed Feb 25, 2020 ↗, against the 10-K filed Feb 22, 2019 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: company letter, Dec 17, 2019, closing letter, 2020-01-22

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 8 letters filed since 2019-12-04. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSM/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.